You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab

Alerts

Article menu

Download PDFPDF

Late-breaking abstracts
Biomarkers, immune monitoring, and novel technologies
760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address